Condensed interim assertion of revenue and loss for the 9 month ended 31 March 2025 (in Rupees) |
2025 |
2024 |
%Change |
Gross sales – Internet |
10,100,185,059 |
9,535,266,706 |
6% |
Price of Gross sales |
(8,643,865,934) |
(8,192,103,683) |
6% |
Gross Revenue |
1,456,319,125 |
1,343,163,023 |
8% |
Administrative Bills |
161,904,092 |
154,757,727 |
5% |
Promoting Bills |
119,703,970 |
100,497,146 |
19% |
Working Revenue |
1,174,711,063 |
1,087,908,150 |
8% |
Monetary (Price) / Earnings |
(231,505,104) |
(200,800,962) |
15% |
Different Earnings/(Loss) |
165,818,206 |
312,952,864 |
-47% |
Different Bills |
(80,335,099) |
(82,062,737) |
-2% |
Revenue earlier than earnings taxes and ultimate tax |
1,028,689,066 |
1,117,997,315 |
-8% |
Taxation – Ultimate taxes |
(4,004) |
(255,970) |
-98% |
Revenue earlier than earnings tax |
1,028,685,062 |
1,117,741,345 |
-8% |
Taxation – Earnings tax |
(349,842,286) |
(436,344,074) |
-20% |
Revenue after earnings tax |
678,842,776 |
681,397,271 |
0% |
Earnings per share (EPS) – Fundamental and Diluted |
2.97 |
2.98 |
|
#Citi #Pharma #posts #flat #9MFY25 #revenue #Rs680m
Leave a Reply